Further Access. List shall provide Revance on a continuing basis, access to the applicable List Intellectual Property and Materials, as described in Sections 1.11 and 2.2(b), as may be necessary for Revance to perform the Manufacturing Responsibilities, and shall give Revance prompt notice of any changes in the List Intellectual Property, such as new or altered protocols, standard operating procedures, equipment specifications, records, tests, results, and other documents, necessary for the manufacture of Product or in obtaining or maintaining registration or regulatory approval. However, notwithstanding anything to the contrary above, after FDA marketing approval of the first Product, List shall only be required to give Revance notice of any changes to the List Intellectual Property on an annual basis.
Appears in 2 contracts
Sources: License and Service Agreement (Revance Therapeutics, Inc.), License and Service Agreement (Revance Therapeutics, Inc.)